Search results for " Remission"

Dose adjustments and discontinuation in TNF inhibitors treated patients: when and how. A systematic review of literature.

2018

Objectives To review the available evidence concerning the possibility of discontinuing and/or tapering the dosage of TNF inhibitors (TNFi) in RA patients experiencing clinical remission or low disease activity. Methods A systematic review of the literature concerning the low dosage and discontinuation of TNFi in disease-controlled RA patients was performed by evaluation of reports published in indexed international journals (Medline via PubMed, EMBASE), in the time frame from 8 April 2013 to 15 January 2016. Results We analysed the literature evaluating the efficacy and the safety of two different strategies using TNFi, decreasing dosage or discontinuation, in patients experiencing clinica…

MR-Mammographie zur Responsekontrolle bei primärer Chemobrachytherapie des BET-inoperablen Mammakarzinoms

2001

Ziel: Evaluierung (1) moglicher storender Effekte neoadjuvanter Chemobrachytherapie auf die MR-Mammographie, (2) der Eignung der MRM zur Bestimmung der Resttumorgrose nach Therapie und (3) der Eignung der MRM zur Prognose des Gesamtansprechens nach den ersten Therapiezyklen. Methoden: 14 Patientinnen, die an einer praoperativen Tumorreduktionstherapie (4 Zyklen Chemotherapie kombiniert mit interstitieller Radiotherapie) teilnahmen, wurden mittels dynamischer MR-Mammographie (1 T, zeitliche Auflosung 93 s, raumliche Auflosung 1,9 mm, 0,1 mmol/kg GdDTPA) vor Therapie, nach den ersten beiden Chemotherapiezyklen, nach der Radiotherapie und dem dritten Zyklus sowie nach Therapieabschluss untersu…

Tinea imbricata in Papua-Neuguinea: Behandlungsversuch mit Griseofulvin und Haloprogin bei einer Population des Gogol-Valley, Madang Province

2009

Zusammenfassung: In zwei Dorfern des Gogol Valley (Papua-Neuguinea) wurden satliche 47 an Tinea imbricata erkrankten Personen erfas, wovon 39 einer Griseofuhin®- bzw. Mycan-den®-Therapie oder Kombination zugefuhrt wurden. Die Zuweisung zu den unterschiedlichen Behandlungsgruppen erfolgte anhand des Alters und des prozentualen Befalls der Korperoberflache. Die Therapiedauer betrug maximal 4 Wochen, der Beobachtungszeitraum insgesamt 6 Wochen. Eine Remission des Hautbefalls erfolgte fur beide Therapeutika von der 2. Behand-lungswoche an. Rezidive traten jedoch schon 1 Woche nach Therapieende auf. Es konnten Unterschiede in der Altersverteilung der Erkrankten in beiden Dorfern festgestellt wer…

Remission phase in children diagnosed with type 1 diabetes (T1D) in years 2012-2013 in Silesia, Poland – an observational study

2019

Background/Objective The study aimed to analyze the frequency of partial remission (PR) and its association with chosen clinical and laboratory factors among pediatric patients with newly diagnosed type 1 diabetes (T1D). The long‐term effect of PR on chosen parameters was also investigated. Methods In 194 patients (95 girls) aged 8.1 ± 4.3 years, we analyzed data at T1D onset: glycemia, pH, C‐peptide, antibodies, weight, and concomitant autoimmune diseases. Anthropometric parameters, daily insulin requirement (DIR), and HbA1c 2 and 4 years after T1D diagnosis were also analyzed. We determined PR based on HbA1c and DIR measurements at least every 3 months. Results PR occurred in 59% of patie…

Spontaneous Remission of Recalcitrant Warts in Girls After Human Papillomavirus Vaccination

2016

Spontaneous tumour regression in keratoacanthomas is driven by Wnt/retinoic acid signalling cross-talk

2014

A fundamental goal in cancer biology is to identify the cells and signalling pathways that are keys to induce tumour regression. Here we use a spontaneously self-regressing tumour, cutaneous keratoacanthoma (KAs), to identify physiological mechanisms that drive tumour regression. By using a mouse model system that recapitulates the behaviour of human KAs, we show that self-regressing tumours shift their balance to a differentiation programme during regression. Furthermore, we demonstrate that developmental programs utilized for skin hair follicle regeneration, such as Wnt, are hijacked to sustain tumour growth and that the retinoic acid (RA) signalling pathway promotes tumour regression by …

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

2018

It is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) in experimental trials on treatment-free remission (TFR). We collected a total of 293 Italian patients with chronic phase CML who discontinued TKI in deep molecular response. Seventy-two percent of patients were on treatment with imatinib, and 28% with second generation TKI at the time of discontinuation. Median duration of treatment with the last TKI was 77 months [Interquartile Range (IQR) 54;111], median duration of deep molecular response was 46 months (IQR 31;74). Duration of treatment with TKI and duration of deep molecular response were shorter with second generation TK…

[Cost of hospital-based management of acute myeloid leukemia: from analytical to procedure-based tarification]

2006

International audience; The confrontation of the macro- and micro-economic approaches of hospital costs is a recurrent question, in particular for pathologies where length of stay is highly variable, like acute myeloid leukemias (AML). This monocentric and retrospective study compares direct hospital medical costs of induction and relapse treatment sequences for AML, valued according to four different approaches: the analytic accounting system of our hospital, the French Diagnosis Related Group (DRG) cost databases of hospital discharges (readjusted, or not, to actual hospital stay duration), and official tariffs from the new French DRG prospective payment system. The average cost of hospit…

Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide

2015

Treatment of acute promyelocytic leukaemia (APL) with arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) is highly effective first-line therapy, although approximately 5-10% of patients relapse. Tamibarotene is a synthetic retinoid with activity in APL patients who relapse after chemotherapy and ATRA, but has not been studied in relapse after treatment with ATO and ATRA. We report on a phase II study of tamibarotene in adult patients with relapsed or refractory APL after treatment with ATRA and ATO (n = 14). Participants were treated with tamibarotene (6 mg/m(2) /d) during induction and for up to six cycles of consolidation. The overall response rate was 64% (n = 9), the rate of comp…

Erythrocyte deformability and hemorheological profile in multiple myeloma

2018

The hemorheological profile in multiple myeloma (MM) has been extensively studied. Our investigation regarded the behavior of whole-blood viscosity, plasma viscosity and erythrocyte deformability in MM. We enrolled 24 MM patients; 13 of them had been recently diagnosed and were at the initial stage of therapy, 6 were on consolidation/conservation therapy and 5 had achieved a complete remission. On fasting venous blood we evaluated whole-blood and plasma viscosity at high and low shear rates, haematocrit, the ratios between whole-blood viscosity (at high and low shear rate) and haematocrit×100, the ratio between plasma viscosity at low and high shear rate and the erythrocyte deformability ex…